Virus Or Bacteriophage Patents (Class 424/93.6)
  • Patent number: 10654839
    Abstract: Provided are compounds of Formula (II) that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: May 19, 2020
    Assignees: Ottawa Hospital Research Institute, University of Ottawa
    Inventors: Jean-Simon Diallo, Christopher Noyce Boddy, Mark Dornan, Ramya Krishnan, Rozanne Arulanandam, Fabrice Le Boeuf, Jeffrey Smith, Andrew Macklin
  • Patent number: 10639337
    Abstract: The present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a Coxsackie B3 group virus or a modified form thereof, wherein the cells of the cancer express a heparan sulfate (HS) receptor on their surface and the virus binds to said HS receptor, enters and accumulates in the cancer cells, whereby at least some cancer cells undergo viral lysis.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: May 5, 2020
    Assignee: TECHNISCHE UNIVERSITÄT BERLIN
    Inventors: Henry Fechner, Ahmet Hazini, Vanessa Brueckner
  • Patent number: 10596258
    Abstract: A method for binding an active substance or an active agent to an activated autologous blood nosode comprises a) dissolving blood of a patient in an aqueous or aqueous/ethanol medium or triturating blood of a patient with an excipient approved for globules according to HAB [Homeopathic Pharmacopoeia] in order to obtain a first mixture; b) activating the first mixture by exposure of the first mixture to magnetic pulses having frequencies of the magnet field periods within a range from approximately 0.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: March 24, 2020
    Assignee: Yeno Awareness BV
    Inventor: Claudia Bettina Klein
  • Patent number: 10561761
    Abstract: Provided herein are polymer and metal organic frameworks (MOFs) composites, and methods of use and preparation thereof. In particular, Poly(polyethyleneglycol citrate-co-N-isopropylacrylamide) (PPCN) and copper MOF composites are provided.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 18, 2020
    Assignee: Northwestern University
    Inventors: Jisheng Xiao, Guillermo A. Ameer
  • Patent number: 10525091
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 7, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • Patent number: 10499651
    Abstract: Methods and compositions are provided for preventing or reducing symptoms or disease associated with Xylella fastidiosa or Xanthomonas axonopodis in a plant. The invention provides novel bacteriophages virulent to Xylella fastidiosa or Xanthomonas axonopodis, including XfaMija and XfaMijo, and further provides methods for treating or preventing Pierce's Disease or Citrus Canker in plants.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: December 10, 2019
    Assignee: The Texas A&M University System
    Inventors: Carlos F. Gonzalez, Stephen J. Ahern, Mayukh Das, Ryland F. Young, III, Tushar Suvra Bhowmick
  • Patent number: 10478401
    Abstract: The invention relates to methods for encapsulating a material comprising the steps of: (a) providing an aqueous solution or suspension of the material that is to be encapsulated, (b) warming the aqueous solution or suspension to a temperature that is sufficient to enable dissolution of a first biocompatible polymer in the aqueous solution or suspension without adversely affecting the properties of the material to be encapsulated, (c) dissolving the first biocompatible polymer in the aqueous solution or suspension, (d) de-aerating the solution or suspension obtained in step (c), (e) emulsifying the solution or suspension obtained in (d) in a biocompatible oil comprising a surfactant to create microdroplets, and (f) hardening the microdroplets by dropwise addition of an aqueous solution comprising Zn2+ ions and a second biocompatible polymer to form microcapsules; the invention further relates to microcapsules obtained by methods of the invention and their uses.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: November 19, 2019
    Assignee: Proteon Pharmaceuticals S.A.
    Inventors: Elzbieta Gorecka, Jaroslaw Dziadek, Wojciech Ambroziak
  • Patent number: 10329539
    Abstract: The present disclosure provides compositions including recombinant B11 bacteriophages, methods for making the same, and uses thereof. The recombinant B11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 25, 2019
    Assignee: THE CHARLES STARK DRAPER LABORATORY INC.
    Inventors: Connor McBrine, Georgiana Kourepenos, Parker Dow, Jason Holder
  • Patent number: 10286019
    Abstract: The present invention relates to a panel of bacteriophage, wherein the panel comprise any one or more bacteriophage selected from the group consisting of:—NCTC 12081404, NCTC 12081405, NCTC 12081406, NCTC 12081407, NCTC 12081408, NCTC 12081409 and NCTC 12081410. The invention also relates to the use of such panels for treating C. difficile infection, or for prophylactic treatment of subjects not yet colonized by C. difficile or that have been colonized but the colonization has not yet progressed to infection.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: May 14, 2019
    Assignee: University of Leicester
    Inventor: Martha Clokie
  • Patent number: 10286062
    Abstract: The present invention includes an isolated antigen against influenza A and a method of making the same that includes an ectodomain of influenza A Matrix Protein 2 (M2e) and a stem region of an influenza A hemagglutinin 2 (HA2) protein and an adjuvant. The invention further includes formulating the antigen into an isolated immune response stimulating fusion protein and/or a vaccine.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: May 14, 2019
    Assignee: Texas Tech University System
    Inventors: Mingtao Zeng, Junwei Li
  • Patent number: 10265356
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-4 that is isolated from the nature and can kill specifically enteroinvasive E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12663BP), and a method for preventing and treating the infections of enteroinvasive E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin, Dong Min Kang
  • Patent number: 10265353
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-CHP-1 that is isolated from the nature and can kill specifically enterohemorrhagic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12660BP), and a method for preventing and treating the infections of enterohemorrhagic E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin
  • Patent number: 10265354
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-CHP-2 that is isolated from the nature and can kill specifically enteropathogenic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12661BP), and a method for preventing and treating the infections of enteropathogenic E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin
  • Patent number: 10260049
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid ?1 protein and expresses a mutated reoviral outer capsid ?3 protein.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: April 16, 2019
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Randal N. Johnston
  • Patent number: 10206974
    Abstract: The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: February 19, 2019
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Martin Neville Shelton
  • Patent number: 10174295
    Abstract: The present disclosure provides compositions including recombinant K1E bacteriophages, methods for making the same, and uses thereof. The recombinant K1E bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: January 8, 2019
    Assignee: THE CHARLES STARK DRAPER LABORATORY, INC.
    Inventors: Sarah Gruszka, Jason Holder
  • Patent number: 10166264
    Abstract: The present invention relates to a bacteriophage having a specific bactericidal activity against Salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The bacteriophage of the present invention has a specific bactericidal activity against Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis or Salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 1, 2019
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Si Yong Yang, Jae Won Kim, Young Wook Cho, Young Sa Kim, Eun Mi Shin
  • Patent number: 9999237
    Abstract: Method of inhibiting the growth of Salmonella in a chicken, comprising administering at least one strain of bacteriophage that lyses at least one Salmonella serovar to a chicken in need thereof, wherein the at least one strain of bacteriophage is a strain selected from PCM F/00069 (strain 8sent1748), PCM F/00070 (strain 8sent65) and PCM F/00071 (strain 3sent1).
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: June 19, 2018
    Assignee: PROTEON PHARMACEUTICALS S.A.
    Inventors: Jaroslaw Dastych, Jaroslaw Dziadek, Elzbieta Gorecka, Anna Rumijowska-Galewicz, Arkadiusz Wojtasik, Ewelina Wojcik
  • Patent number: 9957526
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: May 1, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Jianbin Wang
  • Patent number: 9938506
    Abstract: Provided is a novel bacteriophage ?CJ23 (KCCM11365P). In addition, the present invention relates to an antibacterial composition including the bacteriophage ?CJ23 (KCCM11365P) as an active ingredient. Further, provided is a method of preventing and/or treating infectious diseases by avian pathogenic Escherichia coli (APEC) in birds using the bacteriophage ?CJ23 (KCCM11365P) or the antibacterial composition containing the bacteriophage ?CJ23 (KCCM11365P) as an active ingredient.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: April 10, 2018
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Hyo Seel Seo, Eun Mi Shin, Gi Duk Bae, Jae Won Kim
  • Patent number: 9937196
    Abstract: In this application is described the complete genomic sequence of avian parmyxovirus type 2, strains Yucaipa, England, Kenya and Bangor. The sequences are useful for production of recombinant infective virus, a virus vector, for vaccine development and for therapeutic compositions.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: April 10, 2018
    Assignees: University of Maryland, College Park, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Siba K. Samal, Peter L. Collins
  • Patent number: 9814766
    Abstract: The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-Staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment. The invention is also directed to detecting and identifying altered forms of lysostaphin that possess increased efficacy against infections as compared to wild-type lysostaphin, and forms that generate a minimal or no immune response in a patient. The invention is also directed to method of manufacturing lysostaphin and altered forms of lysostaphin, and compositions that direct the lysostaphin to the site of the infection such as aerosolized nanoparticles.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: November 14, 2017
    Assignee: Longhorn Vaccines and Diagnostics, LLC
    Inventors: Gerald W. Fischer, Richard F. Schuman
  • Patent number: 9808016
    Abstract: The present invention provides a method of shortening pesticidal time of the baculovirus to pest, comprising: (1) preparing a pesticide composition; (2) diluting the pesticide composition 100-3000 times; and (3) spraying the diluted pesticide composition on third or older instars in fields; wherein the pesticide composition comprises: (a) a ryanodine receptor insecticide or a diamides insecticide and (b) baculovirus, wherein the concentration of the ryanodine receptor insecticide or the diamides insecticide is 0.01-75% and the concentration of the nucleopolyhedrovirus is 107-1012 PIB/ml. The pesticide composition of the present invention can effectively reduce the lethal time to the pest compared to the baculovirus alone, and also can increase the control effect of the pest compared to the same concentration of the insecticide, when applied in field.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: November 7, 2017
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Ju-Chun Hsu, Hsiang-Chuan Wang, Cheng-Jen Shih, Shu-Jen Tuan
  • Patent number: 9771622
    Abstract: Methods and systems are provided for packaging reporter nucleic acid molecules into non-replicative transduction particles for use as reporter molecules. The non-replicative transduction particles can be constructed from viruses and use viral transduction and replication systems. The reporter nucleic acid molecules include a reporter gene, such as a reporter molecule or selectable marker, for detecting target genes or cells. Methods and systems are provided for detection of cells and target nucleic acid molecules using the non-replicative transduction particles as reporter molecules.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: September 26, 2017
    Assignee: Geneweave Biosciences, Inc.
    Inventors: Diego Ariel Rey, Nikol de Forest, Heather Cox, Soni Shukla
  • Patent number: 9752200
    Abstract: Methods and systems are provided for packaging reporter nucleic acid molecules into non-replicative transduction particles for use as reporter molecules. The non-replicative transduction particles can be constructed from viruses and use viral transduction and replication systems. The reporter nucleic acid molecules include a reporter gene, such as a reporter molecule or selectable marker, for detecting target genes or cells. Methods and systems are provided for detection of cells and target nucleic acid molecules using the non-replicative transduction particles as reporter molecules.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: September 5, 2017
    Assignee: Geneweave Biosciences, Inc.
    Inventors: Diego Ariel Rey, Nikol de Forest, Heather Cox, Soni Shukla
  • Patent number: 9744175
    Abstract: The invention provides for compositions for treating a cancer or an inflammatory disorder comprising a combination of agents in a pharmaceutically acceptable carrier, wherein said agents comprise: (i) a non-covalent DNA binding agent; and (ii) an anti-cancer or anti-inflammatory agent.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: August 29, 2017
    Assignee: INDUS PHARMACEUTICALS, INC.
    Inventors: Pravin R. Chaturvedi, Palaniyandi Manivasakam, Steven Grossman, Sharon Cantor
  • Patent number: 9687514
    Abstract: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: June 27, 2017
    Assignee: Biocontrol Limited
    Inventors: James Soothill, Catherine Hawkins, David Harper
  • Patent number: 9657277
    Abstract: Provided is a novel bacteriophage ?CJ19 (KCCM11361P). In addition, the present invention relates to an antibacterial composition including the bacteriophage ?CJ19 (KCCM11361P) as an active ingredient. Further, the present invention is a method of preventing and/or treating infectious diseases by enterotoxigenic Escherichia coli in animals except for humans using the bacteriophage ?CJ19 (KCCM11361P) or the antibacterial composition containing the bacteriophage ?CJ19 (KCCM11361P) as an active ingredient.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: May 23, 2017
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Eun Mi Shin, Gi Duk Bae, Jae Won Kim
  • Patent number: 9650272
    Abstract: There is provided a safe, natural, environmentally sound means of controlling bacterial contamination, corrosion, and souring of oil and gas wells and reservoirs that result from bacteria-contaminated water in a well. In one aspect it is a process for remediation of souring of petroleum reservoirs and coalbeds by adding to the water used in flooding and “fracing” operations an effective amount of virulent (non-lysogenic) bacteriophages (phages) specific for problematic target bacteria. The invention also provides a means for combating loss of effectiveness of bacterial control by staging bacteriophage production and application to control dominant and sub-dominant target bacteria in a community of target bacteria.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: May 16, 2017
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Elizabeth J. Summer, Mei Liu, Neil S. Summer, Douglas Baldwin
  • Patent number: 9603909
    Abstract: The present invention relates to a composition for improving the stability of bacteriophage originated lysin proteins greatly even when the composition contains the bacteriophage originated lysin proteins at a high concentration. More precisely, the present invention relates to a method and a composition for improving significantly the stability of SAL-1 or LysK, the bacteriophage originated lysin protein, included at a high concentration in the composition.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: March 28, 2017
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Gi Mo Jung, Sang Hyeon Kang
  • Patent number: 9540420
    Abstract: A mucosal vaccine producing an antigen-specific mucosal IgA and a blood IgG in the levels capable of exerting an effective immune induction and an infection-preventing effect, which comprises: (a) an AD vehicle consisting of a synthetic peptide and a lipid(s), wherein the synthetic peptide consisting of the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20); (b) a carboxylvinyl polymer; and, (c) an antigenic protein, in an amount incapable of producing a sufficient mucosal IgA and blood IgG for exerting an effective immune induction and an infection-preventing effect when used by itself. The mucosal vaccine of the invention has an antibody producing ability which is more potent than those of mucosal vaccines of the prior art, and as a result it can exert an excellent effect even with an extremely small amount of an antigen.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: January 10, 2017
    Assignee: TOKUSHIMA UNIVERSITY
    Inventors: Hiroshi Kido, Dai Mizuno
  • Patent number: 9534207
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: January 3, 2017
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
  • Patent number: 9493564
    Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 15, 2016
    Assignee: APTEVO RESEARCH AND DEVELOPMENT LLC
    Inventors: Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
  • Patent number: 9463240
    Abstract: An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidization device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: October 11, 2016
    Assignee: NOVARTIS AG
    Inventors: Harald Rueckl, Hanno Scheffczik
  • Patent number: 9457132
    Abstract: Medical devices that are resistant to biofilm development and methods of the manufacture of biofilm resistant medical devices are provided. One or more bacteriophages are tethered to the surface of a medical device or a hydrogei-type coating on the surface of the device by covalent bonding while maintaining bacteriophage infective or lytic activity. The presence of the bacteriophages on a medical device, such as an indwelling medical device, prevents biofilm formation or reduces existing biofilm formation on the surface of the device when in use. These devices address the long felt need for biofilm resistant devices that increase safety and reduce complications normally associated with prior indwelling or other medical devices.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: October 4, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rodney Martin Donlan, Susan Marie Lehman, Andres J. Garcia
  • Patent number: 9439436
    Abstract: Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an aryl carbamate as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an aryl carbamate compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or a plant defense activator.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: September 13, 2016
    Assignee: North Carolina State University
    Inventors: Christian Melander, Steven A. Rogers
  • Patent number: 9388453
    Abstract: Methods and systems are provided for packaging reporter nucleic acid molecules into non-replicative transduction particles for use as reporter molecules. The non-replicative transduction particles can be constructed from viruses and use viral transduction and replication systems. The reporter nucleic acid molecules include a reporter gene, such as a reporter molecule or selectable marker, for detecting target genes or cells. Methods and systems are provided for detection of cells and target nucleic acid molecules using the non-replicative transduction particles as reporter molecules.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 12, 2016
    Assignee: GENEWEAVE BIOSCIENCES, INC.
    Inventor: Diego Ariel Rey
  • Patent number: 9388427
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: July 12, 2016
    Assignee: BIOVEC, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • Patent number: 9382298
    Abstract: The invention relates to a polypeptide, a corresponding nucleic acid molecule, a construct and/or vector and/or cell comprising such nucleic acid molecule and/or a composition comprising said polypeptide, nucleic acid molecule, construct, vector and/or cell. The invention further relates to such composition for medical use, preferably for use in treating an infectious disease. Furthermore, the invention relates to the use of said polypeptide, nucleic acid molecule, construct, vector, cell and/or composition as an antimicrobial, preferably as a food additive or disinfectant, or for detecting bacteria, preferably in a diagnostic application.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: July 5, 2016
    Assignee: Micreos Human Health B.V.
    Inventors: Martin Johannes Loessner, Fritz Eichenseher
  • Patent number: 9289456
    Abstract: In the instant invention, simvastatin (Sim) is used to modulate Vesicular Stomatitis Virus (VSV) infection at the level of viral replication for treatment of cancer. Both lipid-lowering and pleiotropic cellular effects of simvastatin are exploited in this modulation. Simvastatin upregulates the expression of Rae1 and Nup98, therefore altering normal cellular mRNA distribution and reverting VSV's mRNA export block. Furthermore, simvastatin causes redistribution of Flotillin-1, which affects VSV replication/budding. Simvastatin is further used as a neoadjuvant for the selective modulatory control of live VSV oncolytic therapy.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: March 22, 2016
    Assignee: Nova Southeastern University
    Inventors: Paula A. Faria-Waziry, Luigi X. Cubeddu, Ana Maria Castejon
  • Patent number: 9284550
    Abstract: Provided is a single-stranded nucleic acid aptamer specifically binding to Klebsiella pneumoniae, and a method for detecting Klebsiella pneumoniae by using the same. The aptamer of the present disclosure, and a method, a composition, a kit or a sensor of using the same may be used to specifically detect Klebsiella pneumoniae present in an aqueous environment, foods, and medical samples and also be applied in fields such as sanitary conditions of foods and medical diagnosis.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 15, 2016
    Assignee: Korea Institute of Science and Technology
    Inventors: Byoung Chan Kim, Yeon Seok Kim, Jin Yang Chung, Jong Soo Jurng, Min Young Song
  • Patent number: 9278127
    Abstract: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunizing against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolizable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: March 8, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Emmanuel Jules Hanon, Jean Stephenne
  • Patent number: 9193956
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: November 24, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Patent number: 9180151
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: November 10, 2015
    Assignee: SillaJen Biotherapeutics, Inc.
    Inventors: David Kirn, Caroline Breitbach
  • Patent number: 9180150
    Abstract: A poxvirus comprising a defective F2L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: November 10, 2015
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Patent number: 9175047
    Abstract: Peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease are described.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: November 3, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Huw M. Nash, David Allen Annis
  • Patent number: 9096845
    Abstract: A method of preserving organisms in viable form, the method comprising: suspending organisms in a solution of electrospinnable polymer; drawing droplets of said solution through a spinneret; applying an electrostatic field to said droplets under electrospinning conditions; so as to form fibers having a diameter no greater than about 5 ?m within which distinct organisms are encapsulated in viable form.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: August 4, 2015
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Jonathan Charles Kuhn, Eyal Zussman
  • Patent number: 9085777
    Abstract: The present invention includes a method of generating a mutant Herpes Simplex Virus (HSV). In one embodiment, the generated HSV genome includes nucleic acid encoding a nucleic acid sequence of interest. In one step, a nucleic acid vector is provided which includes a nucleic acid encoding first and second site specific recombination sequences and a nucleic acid encoding a nucleic acid sequence of interest between said site specific recombination sequences an HSV is provided, the genome of which comprises third and fourth site specific recombination sequences In another step, the nucleic acid vector and HSV are contacted together with one or more recombinase enzymes capable of catalyzing site specific recombination between the site specific recombination sequences of said nucleic acid vector and said HSV. Another step includes identifying HSV containing the nucleic acid sequence of interest. In some embodiments, the methods are conducted in a cell-free system.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: July 21, 2015
    Assignee: Virttu Biologics Limited
    Inventor: Joe Conner
  • Patent number: 9060974
    Abstract: The present invention is within the field of oncolytic virotherapy. Oncolytic virotherapy is a strategy using viruses, naturally occurring or genetically modified, to selectively target and destroy tumor cells while leaving surrounding non-malignant cells unharmed Here, an engineered respiratory syncytial virus (RSV), with the NS1 gene deleted (NS1 gene-deficient RSV, ?NS1 RSV), kills prostate cancer cells, but does not affect normal human cells.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: June 23, 2015
    Inventors: Weidong Zhang, Lixian Jiang, Calvin Cao
  • Publication number: 20150140067
    Abstract: The present invention relates to the identification of microRNAs of the miR-148 family that are involved in the pathogenesis of chronic pulmonary diseases. The present invention relates to micro RNA of the miR-148 family selected from miR-148a, miR-148b and miR-152 for use in the diagnosis, prognosis, prevention and/or therapy of a chronic pulmonary disease. The present invention further relates to miR-148 inhibitors, pharmaceutical compositions comprising such inhibitors, their use in preventing and/or treating chronic pulmonary diseases, and methods for preventing and/or treating chronic pulmonary diseases. The present invention further relates to transgenic, non-human mammals and methods for identifying modulators of miR-148 and methods for diagnosis and/or prognosis of chronic pulmonary diseases.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 21, 2015
    Inventors: Marcus Mall, Raman Agrawal, Martina Muckenthaler